Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Nadya Tarasova · DIVISION OF BASIC SCIENCES - NCI · 2022 · $696,075 — Protein-protein interactions control practically all biological processes. Ability to manipulate these interactions is crucial for finding cures for the vast majority of human diseases. Conventional high-throughput screens for small molecule blockers of protein-protein interactions pr…
Mary N. Carrington · DIVISION OF BASIC SCIENCES - NCI · 2022 · $156,177 — The SARS- CoV-2 Omicron variant (B.1.1.529) was the cause of a new surge of infections globally. With as many as 36 substitutions in the viral spike protein and 59 mutations in total throughout its genome, Omicron has been found to evade neutralization by infection- and vaccine-induce…
Devdoot Majumdar · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · 2022 · $110,871 — The mRNA vaccines against SARS-CoV-2 proved unexpectedly efficacious, but also require a series of booster immunizations to remain protective. Global deployment of these vaccines has been slow, particularly in low- and middle-income countries (LMIC), in part due to the logistical complications assoc…
Aravinda M. DeSilva · UNIV OF NORTH CAROLINA CHAPEL HILL · 2022 · $380,115 — Abstract High-quality recombinant antigens and reliable and accurate SARS-CoV-2 serological assays are urgently needed for surveillance and for defining the immune mechanisms of viral pathogenesis, viral clearance, and protection against reinfection. Core B of the UNC SARS-CoV-2 Serological Sciences…
Taia Wang · STANFORD UNIVERSITY · 2022 · $439,325 — PROJECT 1: SUMMARY As established through decades of research in protective immunity against infectious pathogens, achieving durable immunity against SARS-CoV-2 will require specific functional properties of antibodies, B cells and T cells that need to be defined through detailed repertoire studies.…
Florian Krammer · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $226,649 — PROJECT 1: ABSTRACT Current information indicates that, in persons without cancer, natural infection with SARS-CoV-2 as well as vaccination with COVID-19 vaccine candidates induce antibody responses to the spike protein of the virus which should be protective against future infection. Lung cancer pa…
WILLIAM DEGRADO · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2022 · $3,846,686 — PROJECT 3: TARGETING VIROPORINS AND CORONAVIRUS M PROTEIN SUMMARY Coronaviruses express four structural proteins; spike (S), membrane (M), envelope (E) and nucleocapsid (N), which are essential for efficient viral particle formation. We seek to understand and structurally characterize E and M, and t…
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $175,000 — The emergence of the Wuhan new coronavirus (nCoV) initiated efforts to rapidly develop effective medical countermeasures including vaccines and therapeutics against this severe disease. However, there is limited knowledge on polyclonal antibody responses generated following vaccination or nCoV infec…
Jack T. Stapleton · IOWA CITY VA MEDICAL CENTER · 2022 — We propose to characterize SARS-CoV-2 interactions with human T cells and examine how this influences adaptive and humoral immunity. SARS-CoV-2 (CoV2) is the etiologic agent of COVID-19, the third highly pathogenic coronavirus to emerge as a human pathogen since 2000. CoV-2 causes disease by dysregu…
Savita Pahwa · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2022 · $153,500 — This Competitive Revision application for 2019 Novel Coronavirus research is related to the current grant Immune Dysfunction in HIV+ Opioid Users (DA051202) which is investigating influenza vaccine responses in people with HIV (PWH) who have opioid use disorder (OUD). The premise for the funded gran…
Margaret Juliana McElrath · FRED HUTCHINSON CANCER CENTER · 2022 · $1,077,287 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the first COVID-19 vaccine efficacy trial “A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evalua…
JUAN M SAAVEDRA · GEORGETOWN UNIVERSITY · 2022 · $630,502 — SARS-CoV-2, the virus underlying the current COVID-19 pandemic, not only affects peripheral tissues, it also targets the brain causing microvascular lesions, microhemorrhages and neurological manifestations. The internalization of SARS-CoV-2 is initiated by the binding of the virus spike protein to …
ROBERT A BRODSKY · JOHNS HOPKINS UNIVERSITY · 2022 · $368,356 — The overall goal of this competitive renewal is to define the biology of antiphospholipid antibody syndrome, catastrophic antiphospholipid antibody syndrome and severe forms of COVID-19, and to discover novel biomarkers and therapeutic targets. Complementopathies are diseases where end-organ damage …
Leila Aminova · MIDWEST BIOPROCESSING CENTER, LLC · 2022 · $868,039 — SUMMARY The goal of this project is to develop novel methods to produce sugar building blocks, oligosaccharides, and glycans needed to support and grow R&D related to viral glycobiology at large scale and reasonable prices. This technology will support researchers studying viral pathology, analyses…
Sizun Jiang · BETH ISRAEL DEACONESS MEDICAL CENTER · 2022 · $372,900 — PROJECT SUMMARY/ABSTRACT Distinctive host-pathogen interactions and adaptations are the cornerstones of co-evolution between eukaryotes and their viral pathogens. Given the rapid replication and mutation rates of RNA viruses within their host, understanding these intra-host interactions in their nat…
Matthew Walter Eskew · THERMOCAP LABORATORIES INC. · 2022 · $258,625 — Abstract An attractive feature of using in vitro expression systems to generate biological compounds is the capability to produce a wide variety of compounds (proteins, peptides, antibodies) on various scales, in a cheap and rapid manner. Current methods to analyze any of these produced compounds re…
Sabita Roy · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2022 · $153,500 — Project Summary Infection with Covid-19 has reached pandemic status with more than 125 million confirmed cases and 2.75 million deaths making it one of the most deadliest pandemics in history. It is associated with severe acute respiratory syndrome symptoms with high fatality rates. SARS-CoV-2 infec…
DUXIN SUN · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 · $513,210 — Various nanoparticles (NPs) have been used for delivery of small antigens, which have limited viral mimic features and are more efficacious than soluble antigens in stimulating B-cell immunity. However, these traditional NPs lack characteristics of virus “spiky capsid protein peplomer”, e.g. spiky a…
Goran Bajic · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $795,351 — Immunodominance, the observation that epitopes on an antigen are not “born equal”, poses a major challenge for next-generation vaccines against rapidly evolving pathogens. An underlying premise of this proposal is that in order to engage in rational immunogen design for next-generation vaccines, we …
JOHN P MOORE · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $4,149,892 — Overall Abstract This HIVRAD Program Project renewal application is made in response to PAR-18-319. It contains two Research Projects, one Scientific Core and an Administrative Core, under the direction of Principal Investigator, John P. Moore, PhD (Weill Cornell Medical College; WCMC) and co-Princi…